Vanguard amendment shows 0% stake in ClearPoint Neuro (CLPT) after realignment

Rhea-AI Filing Summary

The Vanguard Group filed Amendment No. 3 on a Schedule 13G/A reporting zero beneficial ownership of ClearPoint Neuro Inc common stock as of 03/13/2026. The filing explains an internal realignment effective 01/12/2026 that caused certain Vanguard subsidiaries to report holdings separately on a "disaggregated basis" in reliance on SEC Release No. 34-39538.

The amendment lists Amount beneficially owned: 0 and Percent of class: 0%, and states Vanguard and its managed accounts have rights to dividends or proceeds where applicable; no other person holds more than 5% according to the filing.

Insights

Institutional Ownership Analyst

Vanguard disaggregation, not a market sale; ownership reported as zero.

The filing shows Amount beneficially owned: 0 and Percent of class: 0% as of 03/13/2026. It attributes the change to an internal reorganization on 01/12/2026, citing SEC Release No. 34-39538 and separate reporting by subsidiaries.

Practical implication: this is a reporting reclassification rather than evidence of divestment in the excerpt provided. Subsequent amendments from Vanguard subsidiaries may show redistributed holdings; follow those filings for holder-level detail.

Compliance & SEC Filings Specialist

Amendment aligns filings with SEC guidance on disaggregated reporting.

The text explicitly cites SEC Release No. 34-39538 and states certain subsidiaries will report "on a disaggregated basis." The filing reiterates Vanguard no longer is deemed to beneficially own securities held by those subsidiaries under that release.

For clarity, examine subsequent Schedule 13G/A entries from Vanguard subsidiaries or related entities to see where previously aggregated positions are now reported.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 3)

ClearPoint Neuro Inc

(Name of Issuer)

Common Stock

(Title of Class of Securities)

(CUSIP Number)

03/13/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP No.

1

Names of Reporting Persons

The Vanguard Group

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

PENNSYLVANIA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0 %

12

Type of Reporting Person (See Instructions)

IA

Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: ClearPoint Neuro Inc
(b)	Address of issuer's principal executive offices: 120 S Sierra Ave, Suite 100, Solana Beach, CA, 92075
Item 2.
(a)	Name of person filing: The Vanguard Group
(b)	Address or principal business office or, if none, residence: 100 Vanguard Blvd.,, Malvern, PA, 19355
(c)	Citizenship: PA
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.:
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 0
(b)	Percent of class: 0 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. The Vanguard Group, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.No one other person's interest in the securities reported herein is more than 5%.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

The Vanguard Group

Signature:	Ashley Grim
Name/Title:	Head of Global Fund Administration
Date:	03/26/2026

FAQ

What does Vanguard report for CLPT ownership in this Schedule 13G/A?

Direct answer: Vanguard reports 0 shares and 0% ownership of ClearPoint Neuro common stock. Supporting context: The amendment dated 03/13/2026 lists Amount beneficially owned: 0 and explains the change follows an internal realignment.

Why does the filing say Vanguard no longer has beneficial ownership for CLPT?

Direct answer: Because of an internal realignment on 01/12/2026 under SEC Release No. 34-39538. Supporting context: The filing states certain Vanguard subsidiaries now report holdings separately on a "disaggregated basis," removing deemed ownership from The Vanguard Group.

Does this Schedule 13G/A indicate Vanguard sold CLPT shares?

Direct answer: The filing attributes the change to reporting disaggregation, not an explicit sale. Supporting context: The amendment explains internal reorganization and separate subsidiary reporting; it does not state sale proceeds or transfers in the provided excerpt.

Where can I find which Vanguard entity now reports any CLPT holdings?

Direct answer: Check subsequent Schedule 13G/A or Form 13 filings by Vanguard subsidiaries for disaggregated holdings. Supporting context: The amendment says subsidiaries will report separately in reliance on SEC Release No. 34-39538; those filings will list holder-level amounts.

Who signed the amendment reporting Vanguard's CLPT position?

Direct answer: Ashley Grim, Head of Global Fund Administration, signed the filing on 03/26/2026. Supporting context: The signature block in the excerpt shows the name and title with the signature date provided.